This site is intended for UK healthcare professionals only. If you are not a UK healthcare professional,
please visit our dedicated site for more information at www.beigene.co.uk
ONE BTK INHIBITOR: MANY POSSIBILITIES
The changing landscape of Waldenström’s Macroglobulinemia (WM)
The purpose of this meeting was to discuss the use of BRUKINSA®▼ (zanubrutinib), a next generation BTK inhibitor, in clinical practice and start the conversation about its place in the patient’s treatment pathway and in hospital protocols. The aim was to facilitate the exchange of best practice and expert opinion in order to benefit patients and provide value to healthcare professionals.
AGENDA
Recordings
Diagnosis, Clinical Features and Indications for WM Therapy
Date of preparation: November 2022. 1122-BRU-PRC-051
An In-Depth Look at the ASPEN Study – Dr Roger Owen and Dr Shirley D’Sa
Date of preparation: November 2022. 1122-BRU-PRC-100
Practical Considerations of BRUKINSA – Dr Jaimal Kothari
Date of preparation: November 2022. 1122-BRU-PRC-102
Current Treatments: BSH Guidelines – Dr Dima El-Sharkawi
Date of preparation: November 2022. 1122-BRU-PRC-097
Select an indication to learn more about BRUKINSA:
